Dendritic cells: Subtypes, life cycle, activation, biological functions and their exploitation in cancer immunotherapy

Dendritic Cells: Types, Life Cycles and Biological Functions

Volumn , Issue , 2010, Pages 1-42

  Breckpot, Karine ^a   Bonehill, Aude ^a   Aerts, Joeri L ^a   Thielemans, Kris ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Dendritic cell; Immune response; Pathogen recognition receptor; Subtype; Tolerance

Indexed keywords

EID: 85017071685     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (257)

1. Steinman, R. M. & Cohn, Z. A. (1973). Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med, 137, 1142-1162.
2. Steinman, R. M., Lustig, D. S. & Cohn, Z. A. (1974). Identification of a novel cell type in peripheral lymphoid organs of mice. 3. Functional properties in vivo. J Exp Med, 139, 1431-1445.
3. Steinman, R. M. & Cohn, Z. A. (1974). Identification of a novel cell type in peripheral lymphoid organs of mice. II. Functional properties in vitro. J Exp Med, 139, 380-397.
4. Naik, S. H. (2008). Demystifying the development of dendritic cell subtypes, a little. Immunol Cell Biol, 86, 439-452.
5. Takeuchi, S. & Furue, M. (2007). Dendritic cells: ontogeny. Allergol Int, 56, 215-223.
6. Sallusto, F. & Lanzavecchia, A. (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med, 179, 1109-1118.
7. Randolph, G. J., Inaba, K., Robbiani, D. F., Steinman, R. M. & Muller, W. A. (1999). Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity, 11, 753-761.
8. Wu, L., D’Amico, A., Winkel, K. D., Suter, M., Lo, D. & Shortman, K. (1998). RelB is essential for the development of myeloid-related CD8alpha-dendritic cells but not of lymphoid-related CD8alpha+ dendritic cells. Immunity, 9, 839-847.
9. Wu, L., Li, C. L. & Shortman, K. (1996). Thymic dendritic cell precursors, relationship to the T lymphocyte lineage and phenotype of the dendritic cell progeny. J Exp Med, 184, 903-911.
10. Traver, D., Akashi, K., Manz, M., Merad, M., Miyamoto, T., Engleman, E. G. & Weissman, I. L. (2000). Development of CD8alpha-positive dendritic cells from a common myeloid progenitor. Science, 290, 2152-2154.
11. Martin, P., del Hoyo, G. M., Anjuere, F., Ruiz, S. R., Arias, C. F., Marin, A. R. & Ardavin, C. (2000). Concept of lymphoid versus myeloid dendritic cell lineages revisited: both CD8alpha(-) and CD8alpha(+) dendritic cells are generated from CD4(low) lymphoid-committed precursors. Blood, 96, 2511-2519.
12. den Haan, J. M. & Bevan, M. J. (2002). Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo. J Exp Med, 196, 817-827.
13. Maldonado-Lopez, R., De Smedt, T., Michel, P., Godfroid, J., Pajak, B., Heirman, C., Thielemans, K., Leo, O., Urbain, J. & Moser, M. (1999). CD8alpha+ and CD8alpha-subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med, 189, 587-592.
14. van Duin, D., Medzhitov, R. & Shaw, A. C. (2006). Triggering TLR signaling in vaccination. Trends Immunol, 27, 49-55.
15. Siegal, F. P., Kadowaki, N., Shodell, M., Fitzgerald-Bocarsly, P. A., Shah, K., Ho, S., Antonenko, S. & Liu. Y. J. (1999). The nature of the principal type 1 interferon-producing cells in human blood. Science, 284, 1835-1837.
16. Nakano, H., Yanagita, M. & Gunn, M. D. (2001). CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J Exp Med, 194, 1171-1178.
17. Segura, E., Wong, J. & Villadangos, J. A. (2009). Cutting edge: B220+CCR9-dendritic cells are not plasmacytoid dendritic cells but are precursors of conventional dendritic cells. J Immunol, 183, 1514-1517.
18. Soumelis, V. & Liu, Y. J. (2006). From plasmacytoid to dendritic cell: morphological and functional switches during plasmacytoid pre-dendritic cell differentiation. Eur J Immunol, 36, 2286-2292.
19. O’Keeffe, M., Hochrein, H., Vremec, D., Caminschi, I., Miller, J. L., Anders, E. M., Wu, L., Lahoud, M. H., Henri, S., Scott, B., Hertzog, P., Tatarczuch, L. & Shortman, K. (2002). Mouse plasmacytoid cells: long-lived cells, heterogeneous in surface phenotype and function, that differentiate into CD8(+) dendritic cells only after microbial stimulus. J Exp Med, 196, 1307-1319.
20. Fitzgerald-Bocarsly, P., Dai, J. & Singh, S. (2008). Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev, 19, 3-19.
21. Fonteneau, J. F., Larsson, M., Beignon, A. S., McKenna, K., Dasilva, I., Amara, A., Liu, Y. J., Lifson, J. D., Littman, D. R. & Bhardwaj, N. (2004). Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J Virol, 78, 5223-5232.
22. Martin, P., Del Hoyo, G. M., Anjuere, F., Arias, C. F., Vargas, H. H., Fernandez, L. A., Parrillas, V. & Ardavin, C. (2002). Characterization of a new subpopulation of mouse CD8alpha+ B220+ dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential. Blood, 100, 383-390.
23. Merad, M. & Manz, M. G. (2009). Dendritic cell homeostasis. Blood, 113, 3418-3427.
24. Kamath, A. T., Henri, S., Battye, F., Tough, D. F. & Shortman. K. (2002). Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. Blood, 100, 1734-1741.
25. Romani, N., Holzmann, S., Tripp, C. H., Koch, F. & Stoitzner, P. (2003). Langerhans cells-dendritic cells of the epidermis. APMIS, 111, 725-740.
26. He, Y., Zhang, J., Donahue, C. & Falo, L. D. Jr. (2006). Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity, 24, 643-656.
27. Larregina, A. T. & Falo, L. D. Jr. (2005). Changing paradigms in cutaneous immunology, adapting with dendritic cells. J Invest Dermatol, 124, 1-12.
28. Grabbe, S., Steinbrink, K., Steinert, M., Luger, T. A. & Schwarz, T. (1995). Removal of the majority of epidermal Langerhans cells by topical or systemic steroid application enhances the effector phase of murine contact hypersensitivity. J Immunol, 155, 4207-4217.
29. Kaplan, D. H., Jenison, M. C., Saeland, S., Shlomchik, W. D. & Shlomchik, M. J. (2005). Epidermal langerhans cell-deficient mice develop enhanced contact hypersensitivity. Immunity, 23, 611-620.
30. Smith, L. G., Weissman, I. L. & Heimfeld, S. (1991). Clonal analysis of hematopoietic stem-cell differentiation in vivo. Proc Natl Acad Sci, U S A 88, 2788-2792.
31. Breckpot, K., Dullaers, M., Bonehill, A., van Meirvenne, S., Heirman, C., de Greef, C., van der Bruggen, P. & Thielemans, K. (2003). Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med, 5, 654-667.
32. Wu, L., D’Amico, A., Hochrein, H., O’Keeffe, M., Shortman, K. & Lucas, K. (2001). Development of thymic and splenic dendritic cell populations from different hemopoietic precursors. Blood, 98, 3376-3382.
33. Manz, M. G., Traver, D., Miyamoto, T., Weissman, I. L. & Akashi, K. (2001). Dendritic cell potentials of early lymphoid and myeloid progenitors. Blood, 97, 3333-3341.
34. D’Amico, A. & Wu, L. (2003). The early progenitors of mouse dendritic cells and plasmacytoid predendritic cells are within the bone marrow hemopoietic precursors expressing Flt3. J Exp Med, 198, 293-303.
35. Karsunky, H., Merad, M., Cozzio, A., Weissman, I. L. & Manz, M. G. (2003). Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med, 198, 305-313.
36. Naik, S. H., Sathe, P., Park, H. Y., Metcalf, D., Proietto, A. I., Dakic, A., Carotta, S., O’Keeffe, M., Bahlo, M., Papenfuss, A., Kwak, J. Y., Wu, L. & Shortman, K. (2007). Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo. Nat Immunol, 8, 1217-1226.
37. Diao, J., Winter, E., Chen, W., Cantin, C. & Cattral, M. S. (2004). Characterization of distinct conventional and plasmacytoid dendritic cell-committed precursors in murine bone marrow. J Immunol, 173, 1826-1833.
38. Fogg, D. K., Sibon, C., Miled, C., Jung, S., Aucouturier, P., Littman, D. R., Cumano, A. & Geissmann, F. (2006). A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. Science, 311, 83-87.
39. Ginhoux, F., Tacke, F., Angeli, V., Bogunovic, M., Loubeau, M., Dai, X. M., Stanley, E. R., Randolph, G. J. & Merad, M. (2006). Langerhans cells arise from monocytes in vivo. Nat Immunol, 7, 265-273.
40. Naik, S. H., Metcalf, D., van Nieuwenhuijze, A., Wicks, I., Wu, L., O’Keeffe, M. & Shortman, K. (2006). Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes. Nat Immunol, 7, 663-671.
41. Onai, N., Obata-Onai, A., Schmid, M. A., Ohteki, T., Jarrossay, D. & Manz, M. G. (2007). Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow. Nat Immunol, 8, 1207-1216.
42. Diao, J., Winter, E., Cantin, C., Chen, W., Xu, L., Kelvin, D., Phillips, J. & Cattral, M. S. (2006). In situ replication of immediate dendritic cell (DC) precursors contributes to conventional DC homeostasis in lymphoid tissue. J Immunol, 176, 7196-7206.
43. Liu, K., Victora, G. D., Schwickert, T. A., Guermonprez, P., Meredith, M. M., Yao, K., Chu, F. F., Randolph, G. J., Rudensky, A. Y. & Nussenzweig, M. (2009). In vivo analysis of dendritic cell development and homeostasis. Science, 324, 392-397.
44. Steinman, R. M., Pack, M. & Inaba, K. (1997). Dendritic cell development and maturation. Adv Exp Med Biol, 417, 1-6.
45. Wu, L. & Liu, Y. J. (2007). Development of dendritic-cell lineages. Immunity, 26, 741-750.
46. Jacobs, B., Wuttke, M., Papewalis, C., Seissler, J. & Schott, M. (2008). Dendritic cell subtypes and in vitro generation of dendritic cells. Horm Metab Res, 40, 99-107.
47. Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y. J., Pulendran, B. & Palucka, K. (2000). Immunobiology of dendritic cells. Annu Rev Immunol, 18, 767-811.
48. Matzinger, P. (2002). The danger model: a renewed sense of self. Science, 296, 301-305.
49. Reise Sousa, C. (2006). Dendritic cells in a mature age. Nat Rev Immunol, 6, 476-483.
50. Steinman, R. M. (2003). Some interfaces of dendritic cell biology. Apmis, 111, 675-697.
51. Akira, S., Uematsu, S. & Takeuchi, O. (2006). Pathogen recognition and innate immunity. Cell, 124, 783-801.
52. Geijtenbeek, T. B. & Gringhuis, S. I. (2009). Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol, 9, 465-479.
53. Barton, G. M. & Kagan, J. C. (2009). A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol, 9, 535-542.
54. Steinman, R. M. & Nussenzweig, M. C. (2002). Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci, U S A 99, 351-358.
55. Steinman, R. M., Hawiger, D., Liu, K., Bonifaz, L., Bonnyay, D., Mahnke, K., Iyoda, T., Ravetch, J., Dhodapkar, M., Inaba, K. & Nussenzweig, M. (2003). Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci, 987, 15-25.
56. Lutz, M. B. & Kurts, C. (2009). Induction of peripheral CD4+ T-cell tolerance and CD8+ T-cell cross-tolerance by dendritic cells. Eur J Immunol, 39, 2325-2330.
57. Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M., Ravetch, J. V., Steinman, R. M. & Nussenzweig, M. C. (2001). Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med, 194, 769-779.
58. Munn, D. H., Sharma, M. D., Lee, J. R., Jhaver, K. G., Johnson, T. S., Keskin, D. B., Marshall, B., Chandler, P., Antonia, S. J., Burgess, R., Slingluff, C. L., Jr. & Mellor, A. L. (2002). Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science, 297, 1867-1870.
59. Rutella, S., Danese, S. & Leone, G. (2006). Tolerogenic dendritic cells: cytokine modulation comes of age. Blood, 108, 1435-1440.
60. Tuyaerts, S., Aerts, J. L., Corthals, J., Neyns, B., Heirman, C., Breckpot, K., Thielemans, K. & Bonehill, A. (2007). Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother, 56, 1513-1537.
61. Bernhard, H., Disis, M. L., Heimfeld, S., Hand, S., Gralow, J. R. & Cheever, M. A. (1995). Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res, 55, 1099-1104.
62. Siena, S., Di Nicola, M., Bregni, M., Mortarini, R., Anichini, A., Lombardi, L., Ravagnani, F., Parmiani, G. & Gianni, A. M. (1995). Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp Hematol, 23, 1463-1471.
63. Berger, T. G., Feuerstein, B., Strasser, E., Hirsch, U., Schreiner, D., Schuler, G. & Schuler-Thurner, B. (2002). Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J Immunol Methods, 268, 131-140.
64. Tuyaerts, S., Noppe, S. M., Corthals, J., Breckpot, K., Heirman, C., De Greef, C., Van Riet, I. & Thielemans, K. (2002). Generation of large numbers of dendritic cells in a closed system using Cell Factories. J Immunol Methods, 264, 135-151.
65. Felzmann, T., Witt, V., Wimmer, D., Ressmann, G., Wagner, D., Paul, P., Huttner, K. & Fritsch, G. (2003). Monocyte enrichment from leukapharesis products for the generation of DCs by plastic adherence, or by positive or negative selection. Cytotherapy, 5, 391-398.
66. Caux, C., Vanbervliet, B., Massacrier, C., Dezutter-Dambuyant, C., de Saint-Vis, B., Jacquet, C., Yoneda, K., Imamura, S., Schmitt, D. & Banchereau, J. (1996). CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J Exp Med, 184, 695-706.
67. Caux, C., Vanbervliet, B., Massacrier, C., Durand, I. & Banchereau, J. (1996). Interleukin-3 cooperates with tumor necrosis factor alpha for the development of human dendritic/Langerhans cells from cord blood CD34+ hematopoietic progenitor cells. Blood, 87, 2376-2385.
68. Lopez, M., Amorim, L., Gane, P., Cristoph, A., Bardinet, D., Abina, A. M., Minty, A. & Bernard, J. (1997). IL-13 induces CD34+ cells isolated from G-CSF mobilized blood to differentiate in vitro into potent antigen presenting cells. J Immunol Methods, 208, 117-129.
69. Szabolcs, P., Moore, M. A. & Young, J. W. (1995). Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha. J Immunol, 154, 5851-5861.
70. Strobl, H., Riedl, E., Scheinecker, C., Bello-Fernandez, C., Pickl, W. F., Rappersberger, K., Majdic, O. & Knapp, W. (1996). TGF-beta 1 promotes in vitro development of dendritic cells from CD34+ hemopoietic progenitors. J Immunol, 157, 1499-1507.
71. Blom, B., Ho, S., Antonenko, S. & Liu, Y. J. (2000). Generation of interferon alpha-producing predendritic cell (Pre-DC)2 from human CD34(+) hematopoietic stem cells. J Exp Med, 192, 1785-1796.
72. Romani, N., Gruner, S., Brang, D., Kampgen, E., Lenz, A., Trockenbacher, B., Konwalinka, G., Fritsch, P. O., Steinman, R. M. & Schuler, G. (1994). Proliferating dendritic cell progenitors in human blood. J Exp Med, 180, 83-93.
73. Dauer, M., Schad, K., Herten, J., Junkmann, J., Bauer, C., Kiefl, R., Endres, S. & Eigler, A. (2005). FastDC derived from human monocytes within 48 h effectively prime tumor antigen-specific cytotoxic T cells. J Immunol Methods, 302, 145-155.
74. Alters, S. E., Gadea, J. R., Holm, B., Lebkowski, J. & Philip, R. (1999). IL-13 can substitute for IL-4 in the generation of dendritic cells for the induction of cytotoxic T lymphocytes and gene therapy. J Immunother, 22, 229-236.
75. Geissmann, F., Prost, C., Monnet, J. P., Dy, M., Brousse, N. & Hermine, O. (1998). Transforming growth factor beta1, in the presence of granulocyte/macrophage colony-stimulating factor and interleukin 4, induces differentiation of human peripheral blood monocytes into dendritic Langerhans cells. J Exp Med, 187, 961-966.
76. Mohamadzadeh, M., Berard, F., Essert, G., Chalouni, C., Pulendran, B., Davoust, J., Bridges, G., Palucka, A. K. & Banchereau, J. (2001). Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J Exp Med, 194, 1013-1020.
77. Chomarat, P., Dantin, C., Bennett, L., Banchereau, J. & Palucka, A. K. (2003). TNF skews monocyte differentiation from macrophages to dendritic cells. J Immunol, 171, 2262-2269.
78. Krutzik, S. R., Tan, B., Li, H., Ochoa, M. T., Liu, P. T., Sharfstein, S. E., Graeber, T. G. P., Sieling, A., Liu, Y. J., Rea, T. H., Bloom, B. R. & Modlin, R. L. (2005). TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. Nat Med, 11, 653-660.
79. Paquette, R. L., Hsu, N. C., Kiertscher, S. M., Park, A. N., Tran, L., Roth, M. D. & Glaspy, J. A. (1998). Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol, 64, 358-367.
80. Buelens, C., Bartholome, E. J., Amraoui, Z., Boutriaux, M., Salmon, I., Thielemans, K., Willems, F. & Goldman, M. (2002). Interleukin-3 and interferon beta cooperate to induce differentiation of monocytes into dendritic cells with potent helper T-cell stimulatory properties. Blood, 99, 993-998.
81. Breckpot, K., Corthals, J., Bonehill, A., Michiels, A., Tuyaerts, S., Aerts, C., Heirman, C. & Thielemans, K. (2005). Dendritic cells differentiated in the presence of IFN{beta} and IL-3 are potent inducers of an antigen-specific CD8+ T cell response. J Leukoc Biol, 78, 898-908.
82. Frick, J. S., Grunebach, F. & Autenrieth, I. B. (2009). Immunomodulation by semi-mature dendritic cells, A novel role of Toll-like receptors and interleukin-6. Int J Med Microbiol.
83. Jonuleit, H., Kuhn, U., Muller, G., Steinbrink, K., Paragnik, L., Schmitt, E., Knop, J. & Enk, A. H. (1997). Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol, 27, 3135-3142.
84. Mailliard, R. B., Wankowicz-Kalinska, A., Cai, Q., Wesa, A., Hilkens, C. M., Kapsenberg, M. L., Kirkwood, J. M., Storkus, W. J. & Kalinski, P. (2004). alpha-type-1 polarized dendritic cells, a novel immunization tool with optimized CTL-inducing activity. Cancer Res, 64, 5934-5937.
85. Napolitani, G., Rinaldi, A., Bertoni, F., Sallusto, F. & Lanzavecchia, A. (2005). Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol, 6, 769-776.
86. Sanchez, P. J., McWilliams, J. A., Haluszczak, C., Yagita, H. & Kedl. R. M. (2007). Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo. J Immunol, 178, 1564-1572.
87. Adams, M., Navabi, H., Jasani, B., Man, S., Fiander, A., Evans, A. S., Donninger, C. & Mason, M. (2003). Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R). Vaccine, 21, 787-790.
88. Michiels, A., Breckpot, K., Corthals, J., Tuyaerts, S., Bonehill, A., Heirman, C., Thielemans, K. & Aerts, J. L. (2006). Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA. Gene Ther, 13, 1027-1036.
89. Bonehill, A., Tuyaerts, S., Van Nuffel, A. M., Heirman, C., Bos, T. J., Fostier, K., Neyns, B. & Thielemans, K. (2008). Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther, 16, 1170-1180.
90. Bonehill, A., Van Nuffel, A. M., Corthals, J., Tuyaerts, S., Heirman, C., Francois, V., Colau, D., van der Bruggen, P., Neyns, B. & Thielemans, K. (2009. Single-step antigen loading and activation of dendritic cells by mRNA electroporatio)n for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res, 15, 3366-3375.
91. Breckpot, K., Heirman, C., Neyns, B. & Thielemans, K. (2004). Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells. J Gene Med, 6, 1175-1188.
92. Rowe, H. M., Lopes, L., Ikeda, Y., Bailey, R., Barde, I., Zenke, M., Chain, B. M. & Collins, M. K. (2006). Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene. Mol Ther, 13, 310-319.
93. Firat, H., Zennou, V., Garcia-Pons, F., Ginhoux, F., Cochet, M., Danos, O., Lemonnier, F. A., Langlade-Demoyen, P. & Charneau, P. (2002). Use of a lentiviral flap vector for induction of CTL immunity against melanoma. Perspectives for immunotherapy. J Gene Med, 4, 38-45.
94. Lopes, L., Dewannieux, M., Gileadi, U., Bailey, R., Ikeda, Y., Whittaker, C., Collin, M. P., Cerundolo, V., Tomihari, M., Ariizumi, K. & Collins, M. K. (2008). Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses. J Virol, 82, 86-95.
95. Palmowski, M. J., Lopes, L., Ikeda, Y., Salio, M., Cerundolo, V. & Collins, M. K. (2004). Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J Immunol, 172, 1582-1587.
96. Dullaers, M., Van Meirvenne, S., Heirman, C., Straetman, L., Bonehill, A., Aerts, J. L., Thielemans, K. & Breckpot, K. (2006). Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther, 13, 630-640.
97. Esslinger, C., Chapatte, L., Finke, D., Miconnet, I., Guillaume, P., Levy, F. & MacDonald. H. R. (2003). In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest, 111, 1673-1681.
98. Beignon, A. S., McKenna, K., Skoberne, M., Manches, O., DaSilva, I., Kavanagh, D. G., Larsson, M., Gorelick, R. J., Lifson, J. D. & Bhardwaj, N. (2005). Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest, 115, 3265-3275.
99. Brown, B. D., Sitia, G., Annoni, A., Hauben, E., Sergi Sergi, L., Zingale, A., Roncarolo, M. G., Guidotti, L. G. & Naldini, L. (2006). In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. Blood.
100. Pichlmair, A., Diebold, S. S., Gschmeissner, S., Takeuchi, Y., Ikeda, Y., Collins, M. K. & Reise Sousa, C. (2007). Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor, 9. J Virol 81, 539-547.
101. Gruber, A., Kan-Mitchell, J., Kuhen, K. L., Mukai, T. & Wong-Staal, F. (2000). Dendritic cells transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions and elicit an HIV-specific cytotoxic T-lymphocyte response in vitro. Blood, 96, 1327-1333.
102. Tan, P. H., Beutelspacher, S. C., Xue, S. A., Wang, Y. H., Mitchell, P., McAlister, J. C., Larkin, D. F., McClure, M. O., Stauss, H. J., Ritter, M. A., Lombardi, G. & George. A. J. (2005). Modulation of human dendritic-cell function following transduction with viral vectors, implications for gene therapy. Blood, 105, 3824-3832.
103. Breckpot, K., Emeagi, P., Dullaers, M., Michiels, A., Heirman, C. & Thielemans, K. (2007). Activation of immature monocyte-derived dendritic cells after transduction with high doses of lentiviral vectors. Hum Gene Ther, 18, 536-546.
104. Breckpot, K., Escors, D., Arce, F., Lopes, L., Karwacz, K., M. Keyaerts, V. L. S., Rogers, N., Reise Sousa, C. & Collins, M. K. (2010) HIV-1 lentiviral vector immunogenicity is mediated by TLR3 and TLR7. J Virol.
105. Boonstra, A., Rajsbaum, R., Holman, M., Marques, R., Asselin-Paturel, C., Pereira, J. P., Bates, E. E., Akira, S., Vieira, P., Liu, Y. J., Trinchieri, G. & O’Garra, A. (2006). Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals. J Immunol, 177, 7551-7558.
106. Kawai, T. & Akira, S. (2008). Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci, 1143, 1-20.
107. Rescigno, M., Martino, M., Sutherland, C. L., Gold, M. R. & Ricciardi-Castagnoli, P. (1998). Dendritic cell survival and maturation are regulated by different signaling pathways. J Exp Med, 188, 2175-2180.
108. Sato, K., Nagayama, H., Tadokoro, K., Juji, T. & Takahashi, T. A. (1999). Extracellular signal-regulated kinase, stress-activated protein kinase/c-Jun N-terminal kinase, and p38mapk are involved in IL-10-mediated selective repression of TNF-alpha-induced activation and maturation of human peripheral blood monocyte-derived dendritic cells. J Immunol, 162, 3865-3872.
109. Re, F. & Strominger, J. L. (2001). Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem, 276, 37692-37699.
110. Caparros, E., Munoz, P., Sierra-Filardi, E., Serrano-Gomez, D., Puig-Kroger, A., Rodriguez-Fernandez, J. L., Mellado, M., Sancho, J., Zubiaur, M. & Corbi, A. L. (2006). DC-SIGN ligation on dendritic cells results in ERK and P13K activation and modulates cytokine production. Blood, 107, 3950-3958.
111. Luft, T., Maraskovsky, E., Schnurr, M., Knebel, K., Kirsch, M., Gorner, M., Skoda, R. Ho, A. D., Nawroth, P. & Bierhaus, A. (2004). Tuning the volume of the immune response: strength and persistence of stimulation determine migration and cytokine secretion of dendritic cells. Blood, 104, 1066-1074.
112. Luft, T., Rodionova, E., Maraskovsky, E., Kirsch, M., Hess, M., Buchholtz, C., Goerner, M., Schnurr, M., Skoda, R. & Ho, A. D. (2006). Adaptive functional differentiation of dendritic cells: integrating the network of extra- and intracellular signals. Blood, 107, 4763-4769.
113. Larange, A., Antonios, D., Pallardy, M. & Kerdine-Romer, S. (2009). TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation. J Leukoc Biol, 85, 673-683.
114. Breckpot, K. & Escors, D. (2009). Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification. Current Drug Targets.
115. Sen, R. & Baltimore, D. (1986). Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell, 47, 921-928.
116. Ghosh, S. & Karin, M. (2002). Missing pieces in the NF-kappaB puzzle. Cell, 109 Suppl, S81-96.
117. Weih, D. S., Yilmaz, Z. B. & Weih, F. (2001). Essential role of RelB in germinal center and marginal zone formation and proper expression of homing chemokines. J Immunol, 167, 1909-1919.
118. Weih, F., Carrasco, D., Durham, S. K., Barton, D. S., Rizzo, C. A., Ryseck, R. P., Lira, S. A. & Bravo, R. (1995). Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell, 80, 331-340.
119. Caamano, J. H., Rizzo, C. A., Durham, S. K., Barton, D. S., Raventos-Suarez, C., Snapper, C. M. & Bravo, R. (1998). Nuclear factor (NF)-kappa B2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses. J Exp Med, 187, 185-196.
120. Franzoso, G., Carlson, L., Poljak, L., Shores, E. W., Epstein, S., Leonardi, A., Grinberg, A., Tran, T., Scharton-Kersten, T., Anver, M., Love, P., Brown, K. & Siebenlist. U. (1998). Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J Exp Med, 187, 147-159.
121. Carrasco, D., Cheng, J., Lewin, A., Warr, G., Yang, H., Rizzo, C., Rosas, F., Snapper, C. & Bravo, R. (1998). Multiple hemopoietic defects and lymphoid hyperplasia in mice lacking the transcriptional activation domain of the c-Rel protein. J Exp Med, 187, 973-984.
122. Poljak, L., Carlson, L., Cunningham, K., Kosco-Vilbois, M. H. & Siebenlist, U. (1999). Distinct activities of p52/NF-kappa B required for proper secondary lymphoid organ microarchitecture: functions enhanced by Bcl-3. J Immunol, 163, 6581-6588.
123. Burkly, L., Hession, C., Ogata, L., Reilly, C., Marconi, L. A., Olson, D., Tizard, R., Cate, R. & Lo, D. (1995). Expression of relB is required for the development of thymic medulla and dendritic cells. Nature, 373, 531-536.
124. Martin, E., O’Sullivan, B., Low, P. & Thomas, R. (2003). Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity, 18, 155-167.
125. Rothwarf, D. M. & Karin, M. (1999). The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci STKE 1999, RE1.
126. Edwards, M. R., Bartlett, N. W., Clarke, D., Birrell, M., Belvisi, M. & Johnston, S. L. (2009). Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther, 121, 1-13.
127. Wang, R. F., Miyahara, Y. & Wang, H. Y. (2008). Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene, 27, 181-189.
128. Lee, C. H., Jeon, Y. T., Kim, S. H. & Song, Y. S. (2007). NF-kappaB as a potential molecular target for cancer therapy. Biofactors, 29, 19-35.
129. Scheidereit, C. (1998). Signal transduction. Docking IkappaB kinases. Nature, 395, 225-226.
130. Courtois, G., Smahi, A. & Israel, A. (2001). NEMO/IKK gamma: linking NF-kappa B to human disease. Trends Mol Med, 7, 427-430.
131. Karin, M. (1999). How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene, 18, 6867-6874.
132. Dawson, S., Hastings, R., Takayanagi, K., Reynolds, S., Low, P., Billett, M. & Mayer. R. J. (1997). The 26S-proteasome: regulation and substrate recognition. Mol Biol Rep, 24, 39-44.
133. Hu, M. C., Wang, Y., Qiu, W. R., Mikhail, A., Meyer, C. F. & Tan, T. H. (1999). Hematopoietic progenitor kinase-1 (HPK1) stress response signaling pathway activates IkappaB kinases (IKK-alpha/beta) and IKK-beta is a developmentally regulated protein kinase. Oncogene, 18, 5514-5524.
134. Li, Q., Van Antwerp, D., Mercurio, F., Lee, K. F. & Verma, I. M. (1999). Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science, 284, 321-325.
135. Takeda, K., Takeuchi, O., Tsujimura, T., Itami, S., Adachi, O., Kawai, T., Sanjo, H., Yoshikawa, K., Terada, N. & Akira, S. (1999). Limb and skin abnormalities in mice lacking IKKalpha. Science, 284, 313-316.
136. Li, Z. W., Chu, W., Hu, Y., Delhase, M., Deerinck, T., Ellisman, M., Johnson, R. & Karin, M. (1999). The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med, 189, 1839-1845.
137. Hacker, H. & Karin, M. (2006). Regulation and function of IKK and IKK-related kinases. Sci STKE, 2006, re13.
138. Dejardin, E., Droin, N. M., Delhase, M., Haas, E., Cao, Y., Makris, C., Li, Z. W., Karin, M., Ware, C. F. & Green, D. R. (2002). The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity, 17, 525-535.
139. Novack, D. V., Yin, L., Hagen-Stapleton, A., Schreiber, R. D., Goeddel, D. V., Ross, F. P. & Teitelbaum, S. L. (2003). The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J Exp Med, 198, 771-781.
140. Senftleben, U., Cao, Y., Xiao, G., Greten, F. R., Krahn, G., Bonizzi, G., Chen, Y., Hu, Y., Fong, A., Sun, S. C. & Karin, M. (2001). Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science, 293, 1495-1499.
141. Lawrence, T. & Bebien, M. (2007). IKKalpha in the regulation of inflammation and adaptive immunity. Biochem Soc Trans, 35, 270-272.
142. Naumann, M. & Scheidereit, C. (1994). Activation of NF-kappa B in vivo is regulated by multiple phosphorylations. EMBO J, 13, 4597-4607.
143. Ito, K., Charron, C. E. & Adcock, I. M. (2007). Impact of protein acetylation in inflammatory lung diseases. Pharmacol Ther, 116, 249-265.
144. Chen, L. F., Mu, Y. & Greene, W. C. (2002). Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J, 21, 6539-6548.
145. Chen, L. F., Williams, S. A., Mu, Y., Nakano, H., Duerr, J. M., Buckbinder, L. & Greene, W. C. (2005). NF-kappaB RelA phosphorylation regulates RelA acetylation. Mol Cell Biol, 25, 7966-7975.
146. Breckpot, K., Aerts-Toegaert, C., Heirman, C., Peeters, U., Beyaert, R., Aerts, J. L. & Thielemans, K. (2009). Attenuated expression of A20 markedly increases the efficacy of double-stranded RNA-activated dendritic cells as an anti-cancer vaccine. J Immunol, 182, 860-870.
147. Kawai, T. & Akira, S. (2007). Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med, 13, 460-469.
148. Coornaert, B., Carpentier, I. & Beyaert, R. (2009). A20: central gatekeeper in inflammation and immunity. J Biol Chem, 284, 8217-8221.
149. Shi, M., Deng, W., Bi, E., Mao, K., Ji, Y., Lin, G., Wu, X., Tao, Z., Li, Z., Cai, X., Sun, S., Xiang, C. & Sun, B. (2008). TRIM30 alpha negatively regulates TLR-mediated NF-kappa B activation by targeting TAB2 and TAB3 for degradation. Nat Immunol, 9, 369-377.
150. Bowie, A. G. (2008). TRIM-ing down Tolls. Nat Immunol 9, 348-350.
151. Barisic, S., Strozyk, E., Peters, N., Walczak, H. & Kulms. D. (2008). Identification of PP2A as a crucial regulator of the NF-kappaB feedback loop, its inhibition by UVB turns NF-kappaB into a pro-apoptotic factor. Cell Death Differ, 15, 1681-1690.
152. Dixit, V. M., Green, S., Sarma, V., Holzman, L. B., Wolf, F. W., O’Rourke, K., Ward, P. A., Prochownik, E. V. & Marks, R. M. (1990). Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J Biol Chem, 265, 2973-2978.
153. Song, X. T., Evel-Kabler, K., Shen, L., Rollins, L., Huang, X. F. & Chen, S. Y. (2008). A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat Med, 14, 258-265.
154. Wertz, I. E., O’Rourke, K. M., Zhou, H., Eby, M., Aravind, L., Seshagiri, S., Wu, P., Wiesmann, C., Baker, R., Boone, D. L., Ma, A., Koonin, E. V. & Dixit, V. M. (2004). De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature, 430, 694-699.
155. Evans, P. C., Ovaa, H., Hamon, M., Kilshaw, P. J., Hamm, S., Bauer, S., Ploegh, H. L. & Smith, T. S. (2004). Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem J, 378, 727-734.
156. Boone, D. L., Turer, E. E., Lee, E. G., Ahmad, R. C., Wheeler, M. T., Tsui, C., Hurley, P., Chien, M., Chai, S., Hitotsumatsu, O., McNally, E., Pickart, C. & Ma, A. (2004). The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol, 5, 1052-1060.
157. Heyninck, K. & Beyaert, R. (2005). A20 inhibits NF-kappaB activation by dual ubiquitin-editing functions. Trends Biochem Sci, 30, 1-4.
158. Zhang, S. Q., Kovalenko, A., Cantarella, G. & Wallach, D. (2000). Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation. Immunity, 12, 301-311.
159. Saitoh, T., Yamamoto, M., Miyagishi, M., Taira, K., Nakanishi, M., Fujita, T., Akira, S. Yamamoto, N. & Yamaoka, S. (2005). A20 is a negative regulator of IFN regulatory factor 3 signaling. J Immunol, 174, 1507-1512.
160. Wang, Y. Y., Li, L., Han, K. J., Zhai, Z. & Shu, H. B. (2004). A20 is a potent inhibitor of TLR3- and Sendai virus-induced activation of NF-kappaB and ISRE and IFN-beta promoter. FEBS Lett, 576, 86-90.
161. Beyaert, R., Heyninck, K. & Van Huffel, S. (2000). A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis. Biochem Pharmacol, 60, 1143-1151.
162. Heyninck, K. & Beyaert, R. (1999). The cytokine-inducible zinc finger protein A20 inhibits IL-1-induced NF-kappaB activation at the level of TRAF6. FEBS Lett, 442, 147-150.
163. Hutti, J. E., Turk, B. E., Asara, J. M., Ma, A., Cantley, L. C. & Abbott, D. W. (2007). IkappaB kinase beta phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF-kappaB pathway. Mol Cell Biol, 27, 7451-7461.
164. Bonehill, A., Heirman, C., Tuyaerts, S., Michiels, A., Breckpot, K., Brasseur, F., Zhang, Y., Van Der Bruggen, P. & Thielemans, K. (2004). Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol, 172, 6649-6657.
165. Breckpot, K., Emeagi, P. U. & Thielemans, K. (2008). Lentiviral vectors for anti-tumor immunotherapy. Curr Gene Ther, 8, 438-448.
166. Breckpot, K., Aerts, J. L. & Thielemans, K. (2007). Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther, 14, 847-862.
167. Ribas, A. (2005). Genetically modified dendritic cells for cancer immunotherapy. Curr Gene Ther 5, 619-628.
168. Van Tendeloo, V. F., Ponsaerts, P. & Berneman, Z. N. (2007). mRNA-based gene transfer as a tool for gene and cell therapy. Curr Opin Mol Ther, 9, 423-431.
169. Andreakos, E., Williams, R. O., Wales, J., Foxwell, B. M. & Feldmann, M. (2006). Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant. Proc Natl Acad Sci, U S A, 103, 14459-14464.
170. Akazawa, T., Shingai, M., Sasai, M., Ebihara, T., Inoue, N., Matsumoto, M. & Seya, T. (2007). Tumor immunotherapy using bone marrow-derived dendritic cells overexpressing Toll-like receptor adaptors. FEBS Lett, 581, 3334-3340.
171. Xu, Y., Darcy, P. K. & Kershaw, M. H. (2007). Tumor-specific dendritic cells generated by genetic redirection of Toll-like receptor signaling against the tumor-associated antigen, erbB2. Cancer Gene Ther, 14, 773-780.
172. Rowe, H. M., Lopes, L., Brown, N., Efklidou, S., Smallie, T., Karrar, S., Kaye, P. M. & Collins, M. K. (2009). Expression of vFLIP in a lentiviral vaccine vector activates NF{kappa}B, matures dendritic cells, and increases CD8+ T-cell responses. J Virol, 83, 1555-1562.
173. Karwacz, K., Mukherjee, S., Apolonia, L., Blundell, M. P., Bouma, G., Escors, D., Collins, M. K. & Thrasher, A. J. (2009). Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy. J Virol 83, 3094-3103.
174. Werner, S. L., Kearns, J. D., Zadorozhnaya, V., Lynch, C., O’Dea, E., Boldin, M. P., Ma, A., Baltimore, D. & Hoffmann, A. (2008). Encoding NF-kappaB temporal control in response to TNF: distinct roles for the negative regulators IkappaBalpha and A20. Genes Dev, 22, 2093-2101.
175. Bhardwaj, N., Young, J. W., Nisanian, A. J., Baggers, J. & Steinman, R. M. (1993). Small amounts of superantigen, when presented on dendritic cells, are sufficient to initiate T cell responses. J Exp Med, 178, 633-642.
176. Bennett, S. R., Carbone, F. R., Karamalis, F., Flavell, R. A., Miller, J. F. & Heath. W. R. (1998). Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature, 393, 478-480.
177. Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R. & Melief, C. J. (1998). T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature, 393, 480-483.
178. Zinkernagel, R. M. & Doherty, P. C. (1974). Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature, 248, 701-702.
179. Caux, C., Massacrier, C., Vanbervliet, B., Dubois, B., Durand, I., Cella, M., Lanzavecchia, A. & Banchereau, J. (1997). CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Blood, 90, 1458-1470.
180. Cella, M., Salio, M., Sakakibara, Y., Langen, H., Julkunen, I. & Lanzavecchia, A. (1999). Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med, 189, 821-829.
181. Romani, N., Koide, S., Crowley, M., Witmer-Pack, M., Livingstone, A. M., Fathman, C. G., Inaba, K. & Steinman, R. M. (1989). Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells. J Exp Med, 169, 1169-1178.
182. Brossart, P. & Bevan, M. J. (1997). Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. Blood, 90, 1594-1599.
183. Bevan, M. J. (1976). Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming. J Immunol, 117, 2233-2238.
184. Guermonprez, P., Saveanu, L., Kleijmeer, M., Davoust, J., Van Endert, P. & Amigorena, S. (2003). ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature, 425, 397-402.
185. Houde, M., Bertholet, S., Gagnon, E., Brunet, S., Goyette, G., Laplante, A., Princiotta, M. F., Thibault, P., Sacks, D. & Desjardins, M. (2003). Phagosomes are competent organelles for antigen cross-presentation. Nature, 425, 402-406.
186. Bretscher, P. & Cohn, M. (1970). A theory of self-nonself discrimination. Science, 169, 1042-1049.
187. Curtsinger, J. M., Schmidt, C. S., Mondino, A., Lins, D. C., Kedl, R. M., Jenkins, M. K. & Mescher, M. F. (1999). Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol, 162, 3256-3262.
188. Matzinger, P. (1994). Tolerance, danger, and the extended family. Annu Rev Immunol, 12, 991-1045.
189. Shi, Y., Evans, J. E. & Rock, K. L. (2003). Molecular identification of a danger signal that alerts the immune system to dying cells. Nature, 425, 516-521.
190. Wallin, R. P., Lundqvist, A., More, S. H., von Bonin, A., Kiessling, R. & Ljunggren, H. G. (2002). Heat-shock proteins as activators of the innate immune system. Trends Immunol, 23, 130-135.
191. Foell, D., Wittkowski, H., Vogl, T. & Roth, J. (2007). S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol, 81, 28-37.
192. Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J. M., Ombrellino, M., Che, J., Frazier, A., Yang, H., Ivanova, S., Borovikova, L., Manogue, K. R., Faist, E., Abraham, E., Andersson, J., Andersson, U., Molina, P. E., Abumrad, N. N., Sama, A. & Tracey. K. J. (1999). HMG-1 as a late mediator of endotoxin lethality in mice. Science, 285, 248-251.
193. Boule, M. W., Broughton, C., Mackay, F., Akira, S., Marshak-Rothstein, A. & Rifkin. I. R. (2004). Toll-like receptor 9-dependent and-independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med, 199, 1631-1640.
194. Leadbetter, E. A., Rifkin, I. R., Hohlbaum, A. M., Beaudette, B. C., Shlomchik, M. J. & Marshak-Rothstein, A. (2002). Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature, 416, 603-607.
195. Barrat, F. J., Meeker, T., Gregorio, J., Chan, J. H., Uematsu, S., Akira, S., Chang, B., Duramad, O. & Coffman, R. L. (2005). Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med, 202, 1131-1139.
196. Lau, C. M., Broughton, C., Tabor, A. S., Akira, S., Flavell, R. A., Mamula, M. J., Christensen, S. R., Shlomchik, M. J., Viglianti, G. A., Rifkin, I. R. & MarshakRothstein, A. (2005). RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med, 202, 1171-1177.
197. Blander, J. M. & Medzhitov, R. (2006). Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature, 440, 808-812.
198. Hofmann, M. A., Drury, S., Fu, C., Qu, W., Taguchi, A., Lu, Y., Avila, C., Kambham, N., Bierhaus, A., Nawroth, P., Neurath, M. F., Slattery, T., Beach, D., McClary, J., Nagashima, M., Morser, J., Stern, D. & Schmidt, A. M. (1999). RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell, 97, 889-901.
199. Scaffidi, P., Misteli, T. & Bianchi, M. E. (2002). Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature, 418, 191-195.
200. Vogl, T., Tenbrock, K., Ludwig, S., Leukert, N., Ehrhardt, C., van Zoelen, M. A., Nacken, W., Foell, D., van der Poll, T., Sorg, C. & Roth, J. (2007). Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med, 13, 1042-1049.
201. Park, J. S., Gamboni-Robertson, F., He, Q., Svetkauskaite, D., Kim, J. Y., D. Strassheim, J. W., Sohn, Yamada, S., Maruyama, I., Banerjee, A., Ishizaka, A. & Abraham, E. (2006). High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol, 290, C917-924.
202. Lafferty, K. J., Warren, H. S. & Woolnough, J. A. (1979). A mediator acting as a costimulator for the development of cytotoxic responses in vitro. Adv Exp Med Biol, 114, 497-501.
203. Lesslauer, W., Koning, F., Ottenhoff, T., Giphart, M., Goulmy, E. & van Rood, J. J. (1986). T90/44 (9.3 antigen). A cell surface molecule with a function in human T cell activation. Eur J Immunol, 16, 1289-1296.
204. Greenwald, R. J., Freeman, G. J. & Sharpe, A. H. (2005). The B7 family revisited. Annu Rev Immunol, 23, 515-548.
205. Watts, T. H. (2005). TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol, 23, 23-68.
206. Aerts-Toegaert, C., Heirman, C., Tuyaerts, S., Corthals, J., Aerts, J. L., Bonehill, A., Thielemans, K. & Breckpot, K. (2007). CD83 expression on dendritic cells and T cells: correlation with effective immune responses. Eur J Immunol, 37, 686-695.
207. Prechtel, A. T., Turza, N. M., Theodoridis, A. A. & Steinkasserer, A. (2007). CD83 knockdown in monocyte-derived dendritic cells by small interfering RNA leads to a diminished T cell stimulation. J Immunol, 178, 5454-5464.
208. Hirano, N., Butler, M. O., Xia, Z., Ansen, S., von Bergwelt-Baildon, M. S., Neuberg, D., Freeman, G. J. & Nadler, L. M. (2006). Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood, 107, 1528-1536.
209. Stephens, G. L., McHugh, R. S., Whitters, M. J., Young, D. A., Luxenberg, D., Carreno, B. M., Collins, M. & Shevach, E. M. (2004). Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol, 173, 5008-5020.
210. van Olffen, R. W., Koning, N., van Gisbergen, K. P., Wensveen, F. M., Hoek, R. M., Boon, L., Hamann, J., van Lier, R. A. & Nolte, M. A. (2009). GITR triggering induces expansion of both effector and regulatory CD4+ T cells in vivo. J Immunol, 182, 7490-7500.
211. Hanabuchi, S., Watanabe, N., Wang, Y. H., Ito, T., Shaw, J., Cao, W., Qin, F. X. & Liu, Y. J. (2006). Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced tumor necrosis factor receptor-ligand (GITRL). Blood 107, 3617-3623.
212. Tuyaerts, S., Van Meirvenne, S., Bonehill, A., Heirman, C., Corthals, J., Waldmann, H., Breckpot, K., Thielemans, K. & Aerts, J. L. (2007). Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells. J Leukoc Biol 82, 93-105.
213. Valzasina, B., Guiducci, C., Dislich, H., Killeen, N., Weinberg, A. D. & Colombo. M. P. (2005). Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood, 105, 2845-2851.
214. Vu, M. D., Xiao, X., Gao, W., Degauque, N., Chen, M., Kroemer, A., Killeen, N., Ishii, N. & Chang Li, X. (2007.) OX40 costimulation turns off Foxp3+ Tregs. Blood, 110, 2501-2510.
215. Voll, R. E., Herrmann, M., Roth, E. A., Stach, C., Kalden, J. R. & Girkontaite, I. (1997). Immunosuppressive effects of apoptotic cells. Nature, 390, 350-351.
216. Morelli, A. E., Larregina, A. T., Shufesky, W. J., Zahorchak, A. F., Logar, A. J., Papworth, G. D., Wang, Z., Watkins, S. C., Falo, L. D. Jr. & Thomson, A. W. (2003). Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: dependence on complement receptors and effect on cytokine production. Blood 101, 611-620.
217. Ip, W. K. & Lau, Y. L. (2004). Distinct maturation of, but not migration between, human monocyte-derived dendritic cells upon ingestion of apoptotic cells of early or late phases. J Immunol, 173, 189-196.
218. Huang, F. P., Platt, N., Wykes, M., Major, J. R., Powell, T. J., Jenkins, C. D. & MacPherson, G. G. (2000). A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J Exp Med 191, 435-444.
219. Liu, K., Iyoda, T., Saternus, M., Kimura, Y., Inaba, K. & Steinman, R. M. (2002). Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med, 196, 1091-1097.
220. Kushwah, R., Oliver, J. R., Zhang, J., Siminovitch, K. A. & Hu, J. (2009). Apoptotic dendritic cells induce tolerance in mice through suppression of dendritic cell maturation and induction of antigen-specific regulatory T cells. J Immunol, 183, 7104-7118.
221. Hill, J. A., Ichim, T. E., Kusznieruk, K. P., Li, M., Huang, X., Yan, X., Zhong, R., Cairns, E., Bell, D. A. & Min, W. P. (2003). Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J Immunol, 171, 691-696.
222. Li, M., Zhang, X., Zheng, X., Lian, D., Zhang, Z. X., Ge, W., Yang, J., Vladau, C., Suzuki, M., Chen, D., Zhong, R., Garcia, B., Jevnikar, A. M. & Min, W. P. (2007). Immune modulation and tolerance induction by RelB-silenced dendritic cells through RNA interference. J Immunol, 178, 5480-5487.
223. Escors, D., Lopes, L., Lin, R., Hiscott, J., Akira, S., Davis, R. J. & Collins, M. K. (2008). Targeting dendritic cell signaling to regulate the response to immunization. Blood, 111, 3050-3061.
224. Tsuchihashi, M., Sakaguchi, Y., Nakamura, M., Sutani, T., Tsuruta, S., Kato, S., Uemura, S., Nishida, Y., Hashimoto, T., Kagoshima, T. & et al. (1995). [Two-color flow cytometry analysis of lymphocyte subsets in patients with acute myocardial infarction and post-myocardial infarction syndrome]. J Cardiol, 26, 69-79.
225. Kubo, T., Hatton, R. D., Oliver, J., Liu, X., Elson, C. O. & Weaver, C. T. (2004). Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells. J Immunol, 173, 7249-7258.
226. Banerjee, D. K., Dhodapkar, M. V., Matayeva, E., Steinman, R. M. & Dhodapkar. K. M. (2006). Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 108, 2655-2661.
227. Misra, N., Bayry, J., Lacroix-Desmazes, S., Kazatchkine, M. D. & Kaveri, S. V. (2004). Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol, 172, 4676-4680.
228. Cederbom, L., Hall, H. & Ivars. F. (2000). CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol, 30, 1538-1543.
229. Tang, Q. & Krummel, M. F. (2006). Imaging the function of regulatory T cells in vivo. Curr Opin Immunol, 18, 496-502.
230. Bronte, V., Apolloni, E., Cabrelle, A., Ronca, R., Serafini, P., Zamboni, P., Restifo, N. P. & Zanovello, P. (2000). Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood, 96, 3838-3846.
231. Gabrilovich, D. I., Velders, M. P., Sotomayor, E. M. & Kast, W. M. (2001). Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol, 166, 5398-5406.
232. Youn, J. I., Nagaraj, S., Collazo, M. & Gabrilovich, D. I. (2008). Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol, 181, 5791-5802.
233. Movahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., De Baetselier, P. & Van Ginderachter, J. A. (2008). Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood, 111, 4233-4244.
234. Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P. & Gabrilovich, D. I. (2001). Increased production of immature myeloid cells in cancer patients, a mechanism of immunosuppression in cancer. J Immunol, 166, 678-689.
235. Gabrilovich, D. (2004). Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol, 4, 941-952.
236. Cheng, P., Corzo, C. A., Luetteke, N., Yu, B., Nagaraj, S., Bui, M. M., Ortiz, M., Nacken, W., Sorg, C., Vogl, T., Roth, J. & Gabrilovich, D. I. (2008). Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med, 205, 2235-2249.
237. Kusmartsev, S., Cheng, F., Yu, B., Nefedova, Y., Sotomayor, E., Lush, R. & Gabrilovich, D. (2003). All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res, 63, 4441-4449.
238. Mirza, N., Fishman, M., Fricke, I., Dunn, M., Neuger, A. M., Frost, T. J., Lush, R. M. Antonia, S. & Gabrilovich, D. I. (2006). All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res, 66, 9299-9307.
239. Kusmartsev, S., Su, Z., Heiser, A., Dannull, J., Eruslanov, E., Kubler, H., Yancey, D., Dahm, P. & Vieweg, J. (2008). Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res, 14, 8270-8278.
240. Pan, P. Y., Wang, G. X., Yin, B., Ozao, J., Ku, T., Divino, C. M. & Chen, S. H. (2008). Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood, 111, 219-228.
241. Daurkin, I., Eruslanov, E., Vieweg, J. & Kusmartsev, S. (2009). Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2'-deoxycytidine. Cancer Immunol Immunother.
242. Fallarino, F., Vacca, C., Orabona, C., Belladonna, M. L., Bianchi, R., Marshall, B., Keskin, D. B., Mellor, A. L., Fioretti, M. C., Grohmann, U. & Puccetti, P. (2002). Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. Int Immunol, 14, 65-68.
243. Hwu, P., Du, M. X., Lapointe, R., Do, M., Taylor, M. W. & Young, H. A. (2000). Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol, 164, 3596-3599.
244. Hill, M., Tanguy-Royer, S., Royer, P., Chauveau, C., Asghar, K., Tesson, L., Lavainne, F., Remy, S., Brion, R., Hubert, F. X., Heslan, M., Rimbert, M., Berthelot, L., Moffett, J. R., Josien, R., Gregoire, M. & Anegon, I. (2007). IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur J Immunol, 37, 3054-3062.
245. Chung, D. J., Rossi, M., Romano, E., Ghith, J., Yuan, J., Munn, D. H. & Young, J. W. (2009). Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood, 114, 555-563.
246. Fallarino, F., Grohmann, U., Vacca, C., Orabona, C., Spreca, A., Fioretti, M. C. & Puccetti, P. (2003). T cell apoptosis by kynurenines. Adv Exp Med Biol, 527, 183-190.
247. Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A. & Mellor, A. L. (2004). Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest, 114, 280-290.
248. Martin-Orozco, N., Wang, Y. H., Yagita, H. & Dong, C. (2006). Cutting Edge: Programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens. J Immunol, 177, 8291-8295.
249. Fife, B. T., Pauken, K. E., Eagar, T. N., Obu, T., Wu, J., Tang, Q., Azuma, M., Krummel, M. F. & Bluestone, J. A. (2009). Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol, 10, 1185-1192.
250. Wang, L., Pino-Lagos, K., de Vries, V. C., Guleria, I., Sayegh, M. H. & Noelle, R. J. (2008). Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci, U S A 105, 9331-9336.
251. de Vries, I. J., Lesterhuis, W. J., Scharenborg, N. M., Engelen, L. P., Ruiter, D. J., Gerritsen, M. J., Croockewit, S., Britten, C. M., Torensma, R., Adema, G. J., Figdor, C. G. & Punt, C. J. (2003). Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res, 9, 5091-5100.
252. Jonuleit, H., Giesecke-Tuettenberg, A., Tuting, T., Thurner-Schuler, B., Stuge, T. B., Paragnik, L., Kandemir, A., Lee, P. P., Schuler, G., Knop, J. & Enk, A. H. (2001). A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer, 93, 243-251.
253. Yamanaka, R., Homma, J., Yajima, N., Tsuchiya, N., Sano, M., Kobayashi, T., Yoshida, S., Abe, T., Narita, M., Takahashi, M. & Tanaka, R. (2005). Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res, 11, 4160-4167.
254. de Vries, I. J., Lesterhuis, W. J., Barentsz, J. O., Verdijk, P., van Krieken, J. H., Boerman, O. C., Oyen, W. J., Bonenkamp, J. J., Boezeman, J. B., Adema, G. J., Bulte, J. W., Scheenen, T. W., Punt, C. J., Heerschap, A. & Figdor, C. G. (2005). Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol, 23, 1407-1413.
255. Verdijk, P., Aarntzen, E. H., Lesterhuis, W. J., Boullart, A. C., Kok, E., van Rossum, M. M., Strijk, S., Eijckeler, F., Bonenkamp, J. J., Jacobs, J. F., Blokx, W., Vankrieken, J. H., Joosten, I., Boerman, O. C., Oyen, W. J., Adema, G., Punt, C. J., Figdor, C. G. & de Vries, I. J. (2009). Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res, 15, 2531-2540.
256. Mullins, D. W., Sheasley, S. L., Ream, R. M., Bullock, T. N., Fu, Y. X. & Engelhard, V. H. (2003). Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med, 198, 1023-1034.
257. Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M. & Matrisian, L. M. (2009). The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res, 15, 5323-5337.